131I-CAM-H2 (131I-SGMIB anti-HER2-VHH1; 131I-SGMIB) is a targeted radionuclide therapeutic drug (TRNT) directed at HER2 expressing cancers. The drug is a single domain antibody fragment (sdAb), a camel antibody, covalently linked to 131I via the linker SGMIB. This is the most advanced drug based on camel antibodies. HER2 was the first target and the radiolabeled molecule aims at becoming an alternative therapy in breast cancer patients.
131I-CAM-H2 completed phase I clinical trial which results were published in June 2018. A phase I/II trial is now under preparation.
Leading Emitter: beta electrons (β–)